Global Health Innovation Technology Models:

Nanobiomedicine

KimberlyHarding¹ 

关键词: Radiology;    Imaging;    Global Health;    Low Income Countries;    Low Middle Income Countries;    mHealth;    ehealth;    Clinical Trials;    Drug Discovery;    CRO;    Infectious Diseases;    Rare Diseases;    Tropical Diseases;    TB;    Public Health;    Health Information Technology;    Health Information Management;    FDA;    WHO;    Open Science;    Open Source: Big Data;    Clinical;    Informatics;    Bioinformatics;    Epidemiology;    Medical Device;    Software;    Hardware;    GCP;    ICH;    Africa;    Tanzania;    HIV;    Malaria;    Clinical Imaging;    Nanotechnology;    Nanomedicine;    Innovation;    Commercialization;    Regulatory;    St;    ards;    Frameworks;    Semantics;    Syntax;    Interoperability;    Business Process;    Product Development;   

DOI  :  10.5772/62921

学科分类：生物科学（综合）

来源: Sage Journals

【 摘 要 】

Chronic technology and business process disparities between High Income, Low Middle Income and Low Income (HIC, LMIC, LIC) research collaborators directly prevent the growth of sustainable Global Health innovation for infectious and rare diseases. There is a need for an Open Source-Open Science Architecture Framework to bridge this divide. We are proposing such a framework for consideration by the Global Health community, by utilizing a hybrid approach of integrating agnostic Open Source technology and healthcare interoperability standards and Total Quality Management principles. We will validate this architecture framework through our programme called Project Orchid. Project Orchid is a conceptual Clinical Intelligence Exchange and Virtual Innovation platform utilizing this approach to support clinical innovation efforts for multi-national collaboration that can be locally sustainable for LIC and LMIC research cohorts. The goal is to enable LIC and LMIC research organizations to accelerate their clinical trial process maturity in the field of drug discovery, population health innovation initiatives and public domain knowledge networks. When sponsored, this concept will be tested by 12 confirmed clinical research and public health organizations in six countries. The potential impact of this platform is reduced drug discovery and public health innovation lag time and improved clinical trial interventions, due to reliable clinical intelligence and bio-surveillance across all phases of the clinical innovation process.

【 授权许可】

CC BY